Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.

Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E.

Eur Heart J. 2007 Feb;28(4):443-9. Epub 2007 Jan 24.

PMID:
17251257
2.
3.

Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.

Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL.

Catheter Cardiovasc Interv. 2010 May 1;75(6):895-902. doi: 10.1002/ccd.22349.

PMID:
20088008
4.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

5.

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.

Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ.

Circulation. 1999 Dec 21-28;100(25):2477-84.

6.

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.

N Engl J Med. 1999 Jul 29;341(5):319-27.

7.

Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction.

Velianou JL, Al-Suwaidi J, Mathew V.

Am J Cardiovasc Drugs. 2002;2(5):315-22. Review.

PMID:
14727961
8.

Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.

Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G.

Platelets. 2012;23(4):274-81. doi: 10.3109/09537104.2011.619602. Epub 2011 Oct 11.

PMID:
21988317
10.

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.

Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up.

N Engl J Med. 2001 Jun 21;344(25):1895-903.

12.

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA.

Am Heart J. 2004 Mar;147(3):457-62. Review.

PMID:
14999194
13.

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.

Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.

Circulation. 2004 Dec 14;110(24):3627-35. Epub 2004 Nov 7.

14.

Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial.

Zeymer U, Tebbe U, Weber M, Vohringer HF, Jaksch R, Bischoff KO, Toepel W, Marsalek P, Horn S, Neuhaus KL; ALKK Study Group.

J Invasive Cardiol. 2003 Jul;15(7):385-9. Erratum in: J Invasive Cardiol. 2003 Sep;15(9):519.

PMID:
12840235
15.

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

Ibbotson T, McGavin JK, Goa KL.

Am J Cardiovasc Drugs. 2003;3(5):381-6. Review.

PMID:
14728074
16.

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis.

DE Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, DE Carlo M, Rakowski T, Gyongyosi M, Dudek D.

J Thromb Haemost. 2011 Dec;9(12):2361-70. doi: 10.1111/j.1538-7836.2011.04513.x.

17.

Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.

Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ.

Circulation. 2000 Jul 4;102(1):28-34.

18.

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators.

Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25.

20.

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ.

Circulation. 1998 Aug 25;98(8):734-41.

Supplemental Content

Support Center